Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments
Pete Anderson(The University of Texas MD Anderson Cancer Center), Alexander J. Chou(Cornell University), Nicholas D. Yeager, Paul A. Meyers(Memorial Sloan Kettering Cancer Center), Cynthia E. Herzog(Memorial Sloan Kettering Cancer Center), Winston W. Huh(The University of Texas MD Anderson Cancer Center), Cristina Oliva(Universidad de Huelva), Karthik Venkatakrishnan(Ono Pharmaceutical (United States)), Robert M. Sutphin(Orlando Regional Medical Center), Eugenie S. Kleinerman(The University of Texas MD Anderson Cancer Center), Dennis P.M. Hughes(The University of Texas MD Anderson Cancer Center), Yatin M. Vyas(University of Iowa), Y. Liu(Millennium Engineering and Integration (United States)), Anne B. Warwick(Uniformed Services University of the Health Sciences), Violet Shen(Ruhr University Bochum), B. Wang(Millennium Engineering and Integration (United States))
Cited by 73
Related Papers
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia
|Nature Genetics|2013|332